Claris Lifesciences gets ANDA nod for Tobramycin Injection
The company has received approval for Tobramycin Injection.
Claris Lifesciences Ltd has announced that it has received ANDA approval for Tobramycin Injection.
Claris Lifesciences Ltd ended at Rs. 217.2, up by Rs. 1.45 or 0.67% from its previous closing of Rs. 215.75 on the BSE.
The scrip opened at Rs. 218.35 and touched a high and low of Rs. 219.8 and Rs. 215.2 respectively. A total of 20943(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 1185.21 crore.
The BSE group 'B' stock of face value Rs. 10 touched a 52 week high of Rs. 266 on 30-Jul-2015 and a 52 week low of Rs. 126.1 on 12-Feb-2016. Last one week high and low of the scrip stood at Rs. 223.65 and Rs. 212.5 respectively.
The promoters holding in the company stood at 60.99 % while Institutions and Non-Institutions held 21.37 % and 17.64 % respectively.
The stock traded above its 50 DMA.